Principal investigator: Dr. Bianca Besteher
IZKF 2019 - 2023
Projektleiterin: Prof. Dr. Britta Qualmann
DFG 2020-2020
In a cohort of 300 participants, multidimensional psychometrics, multimodal MR imaging (T1, rs-fMRI, QSM), acquisition of inflammation-specific laboratory data, and genome-wide sequencing will be performed across a spectrum of depressive symptomatology to characterize biologically distinct subtypes based on these data and to track the dependent clinical course using an app-assisted follow-up over one year.
Principal investigator: Prof. Dr. Martin Walter
BMBF-EU-EraNet-Neuron 2020 - 2023
Ketamine therapies are promising procedures with rapid effects for the treatment of treatment-resistant depression. However, approximately 30-50% of patients do not respond. Therefore, markers that proactively indicate whether patients will respond to treatment with ketamine would be beneficial. This project will investigate potential predictive blood biomarkers in ketamine treatments that have been linked to depression and correlate them with brain imaging biomarkers.
Principal investigator: Prof. Dr. Martin Walter
DFG 2019 - 2023
Ketamine therapies are promising procedures with rapid effects for the treatment of treatment-resistant depression. However, approximately 30-50% of patients do not respond. Therefore, markers that proactively indicate whether patients will respond to treatment with ketamine would be beneficial. This project will investigate potential predictive blood biomarkers in ketamine treatments that have been linked to depression and correlate them with brain imaging biomarkers.
Interrelations between clinical efficacy, connectivity in the executive control and salience network and local glutamate/GABA metabolism
Principal investigator: apl. Prof. Dr. Stefan Smesny
DFG 2019 - 2022
The main objective is to compare the effects of emotion-focused (experiential) and cognitive schema therapy (ST) interventions on deficits in emotion regulation in women with borderline personality disorder (BPD). A randomized, single-blind, parallel-group design will compare clinical effects and effects on connectivity and neurotransmitter metabolism. While the 9-week treatment protocol of particular interest includes emotion-focused interventions, the control condition is limited to cognitive interventions.